PDA

View Full Version : Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma


News
09-19-2011, 05:42 AM
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that top-line data from part one of a two-part Phase 1 study of SPI-1620 in combination with docetaxel was presented in an oral presentation at the 12th International Conference on Endothelin, held in Cambridge, United Kingdom, from September 11-14, 2011. Part one of the study has been completed, while part two is ongoing.

More... (http://www.news-medical.net/news/20110919/Top-line-data-from-Spectrums-SPI-1620-Phase-1-combination-study-on-carcinoma.aspx)